drugset / Trial / NCT06605963

PPV-06 Vaccine in Inflammatory Knee Osteoarthritis

NCT06605963 ↗

Phase 2 Not yet recruiting 204 enrolled Peptinov SAS
RandomizedParallel-groupTriple-blindTreatment

Summary

PPV-06 targets interleukin-6, a key molecule implicated in many inflammatory diseases such osteoarthritis. PPV-06 is used to induce the production of antibodies directed against IL-6. The antibodies produced will neutralize the interleukine-6 involved in the body's inflammatory process. The goal of this clinical trial is to test the safety and efficacy of PPV-06 in participants with Knee Osteoarthritis. The main questions are to evaluate if PPV-06 can reduce pain and improve functioning in participants with knee osteoarthritis, and to evaluate if ¨PPV-06 is safe when administered to participants. Participants will be administered with 6 subcutaneous injections of either PPV-06 or placebo, over a two-year period.

Timeline

Start
2025-12
Primary completion
2028-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PPV-06 Vaccine 10 ug Subcutaneous

Indications